Zacks Research Weighs in on GSK’s FY2027 Earnings (NYSE:GSK)

GSK plc (NYSE:GSK) – Equities researchers at Zacks Research raised their FY2027 EPS estimates for shares of GSK in a note issued to investors on Tuesday, March 25th. Zacks Research analyst E. Bagri now forecasts that the pharmaceutical company will earn $5.05 per share for the year, up from their prior forecast of $5.04. The consensus estimate for GSK’s current full-year earnings is $4.14 per share.

GSK (NYSE:GSK) last posted its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%.

Several other equities research analysts also recently commented on GSK. Morgan Stanley initiated coverage on GSK in a report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 7th. Seven investment analysts have rated the stock with a hold rating and four have given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Stock Performance

GSK stock opened at $38.28 on Thursday. GSK has a twelve month low of $31.72 and a twelve month high of $45.93. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. The company has a market capitalization of $79.24 billion, a P/E ratio of 24.08, a PEG ratio of 1.12 and a beta of 0.58. The stock’s 50 day moving average is $37.01 and its 200 day moving average is $36.81.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be issued a $0.3932 dividend. The ex-dividend date is Friday, February 21st. This represents a $1.57 annualized dividend and a yield of 4.11%. This is a boost from GSK’s previous quarterly dividend of $0.39. GSK’s dividend payout ratio (DPR) is currently 98.74%.

Institutional Investors Weigh In On GSK

Hedge funds have recently added to or reduced their stakes in the stock. Dodge & Cox grew its holdings in shares of GSK by 0.5% in the fourth quarter. Dodge & Cox now owns 68,440,912 shares of the pharmaceutical company’s stock worth $2,314,672,000 after acquiring an additional 353,749 shares during the period. FMR LLC boosted its position in GSK by 82.1% in the fourth quarter. FMR LLC now owns 52,823,032 shares of the pharmaceutical company’s stock worth $1,786,475,000 after purchasing an additional 23,814,104 shares during the last quarter. Primecap Management Co. CA grew its stake in shares of GSK by 70.1% during the 4th quarter. Primecap Management Co. CA now owns 25,261,660 shares of the pharmaceutical company’s stock valued at $854,349,000 after purchasing an additional 10,407,905 shares during the period. Fisher Asset Management LLC increased its position in shares of GSK by 1.4% during the 4th quarter. Fisher Asset Management LLC now owns 18,836,797 shares of the pharmaceutical company’s stock valued at $637,061,000 after purchasing an additional 259,867 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of GSK by 0.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,566,922 shares of the pharmaceutical company’s stock worth $255,914,000 after purchasing an additional 35,134 shares during the period. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.